as 07-26-2024 4:00pm EST
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Founded: | 2008 | Country: | United States |
Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
Market Cap: | 189.8M | IPO Year: | 2017 |
Target Price: | $8.00 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.62 | EPS Growth: | N/A |
52 Week Low/High: | $1.08 - $6.14 | Next Earning Date: | 08-08-2024 |
Revenue: | $84,041,000 | Revenue Growth: | 46.55% |
Revenue Growth (this year): | -10.67% | Revenue Growth (next year): | 36.91% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Bailey John E. (Jack) Jr. | GTHX | President and CEO | Jul 5 '24 | Sell | $2.51 | 7,662 | $19,214.00 | 549,674 | SEC Form 4 |
Malik Rajesh | GTHX | Chief Medical Officer | Jul 5 '24 | Sell | $2.51 | 2,475 | $6,206.56 | 159,312 | SEC Form 4 |
Umstead John W. V | GTHX | Chief Financial Officer | Jul 5 '24 | Sell | $2.51 | 527 | $1,321.56 | 187,718 | SEC Form 4 |
Avagliano Mark | GTHX | Chief Business Officer | Jul 5 '24 | Sell | $2.51 | 2,638 | $6,615.31 | 242,045 | SEC Form 4 |
Thomas Monica R. | GTHX | Chief Legal & People Officer | May 23 '24 | Sell | $4.27 | 5,826 | $24,864.20 | 109,825 | SEC Form 4 |
Umstead John W. V | GTHX | Chief Financial Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 153,245 | SEC Form 4 |
Avagliano Mark | GTHX | Chief Business Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 209,683 | SEC Form 4 |
Malik Rajesh | GTHX | Chief Medical Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 161,787 | SEC Form 4 |
MURDOCK TERRY L | GTHX | Chief Operating Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 95,487 | SEC Form 4 |
Perry Andrew | GTHX | Chief Commercial Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 78,951 | SEC Form 4 |
Bailey John E. (Jack) Jr. | GTHX | President and CEO | May 13 '24 | Sell | $4.79 | 37,258 | $178,421.11 | 452,336 | SEC Form 4 |
Umstead John W. V | GTHX | Chief Financial Officer | Mar 18 '24 | Sell | $3.02 | 6,547 | $19,751.64 | 123,896 | SEC Form 4 |
Malik Rajesh | GTHX | Chief Medical Officer | Feb 12 '24 | Sell | $4.62 | 28,600 | $132,143.44 | 169,938 | SEC Form 4 |
Avagliano Mark | GTHX | Chief Business Officer | Jan 3 '24 | Sell | $2.94 | 721 | $2,121.40 | 117,834 | SEC Form 4 |
Avagliano Mark | GTHX | Chief Business Officer | Jan 3 '24 | Sell | $3.12 | 2,602 | $8,115.38 | 118,555 | SEC Form 4 |
Avagliano Mark | GTHX | Chief Business Officer | Jan 3 '24 | Sell | $3.12 | 758 | $2,364.13 | 121,157 | SEC Form 4 |
Umstead John W. V | GTHX | Chief Financial Officer | Jan 3 '24 | Sell | $2.94 | 111 | $326.60 | 130,443 | SEC Form 4 |
Umstead John W. V | GTHX | Chief Financial Officer | Jan 3 '24 | Sell | $3.12 | 379 | $1,182.06 | 130,554 | SEC Form 4 |
Umstead John W. V | GTHX | Chief Financial Officer | Jan 3 '24 | Sell | $3.12 | 253 | $789.08 | 130,933 | SEC Form 4 |
Perry Andrew | GTHX | Chief Commercial Officer | Jan 3 '24 | Sell | $3.12 | 379 | $1,182.06 | 89,136 | SEC Form 4 |
Perry Andrew | GTHX | Chief Commercial Officer | Jan 3 '24 | Sell | $3.12 | 2,034 | $6,343.84 | 87,102 | SEC Form 4 |
Malik Rajesh | GTHX | Chief Medical Officer | Jan 3 '24 | Sell | $3.12 | 758 | $2,364.13 | 172,920 | SEC Form 4 |
Malik Rajesh | GTHX | Chief Medical Officer | Jan 3 '24 | Sell | $3.12 | 2,261 | $7,051.83 | 170,659 | SEC Form 4 |
Malik Rajesh | GTHX | Chief Medical Officer | Jan 3 '24 | Sell | $2.94 | 721 | $2,121.40 | 169,938 | SEC Form 4 |
Bailey John E. (Jack) Jr. | GTHX | President and CEO | Jan 3 '24 | Sell | $3.12 | 2,592 | $8,084.19 | 498,688 | SEC Form 4 |
GTHX Breaking Stock News: Dive into GTHX Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 hours ago
GlobeNewswire
a day ago
MT Newswires
25 days ago
GlobeNewswire
25 days ago
Clinical Trials Arena
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
The information presented on this page, "GTHX G1 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.